European Patent Office cancels oral opposition proceedings concerning Cantargia’s patent for hematological cancers
In the ongoing opposition proceedings at the European Patent Office (“EPO”) concerning Cantargia AB’s (“Cantargia”) patent for antibody treatment against IL1RAP in hematological cancers, EPO has informed the company that the oral proceedings that were due to take place on 8 February 2018 have been cancelled.Cantargia has two patent families covering IL1RAP as a target for antibody treatment of cancer. In June 2016, a third party filed an opposition against Cantargia’s European patent no. EP 2467403 for antibody treatment against the target IL1RAP on hematological cancers. Opposition